Literature DB >> 27216073

New Regimen for Continuous Infusion of Vancomycin in Critically Ill Patients.

Stefano Cristallini1, Maya Hites2, Hakim Kabtouri1, Jason A Roberts3, Marjorie Beumier1, Frederic Cotton4, Jeffrey Lipman5, Frédérique Jacobs2, Jean-Louis Vincent1, Jacques Creteur1, Fabio Silvio Taccone6.   

Abstract

Despite the development of new agents with activity against Gram-positive bacteria, vancomycin remains one of the primary antibiotics for critically ill septic patients. Because sepsis can alter antimicrobial pharmacokinetics, the development of an appropriate dosing strategy to provide adequate concentrations is crucial. The aim of this study was to prospectively validate a new dosing regimen of vancomycin given by continuous infusion (CI) to septic patients. We included all adult septic patients admitted to a mixed intensive care unit (ICU) between January 2012 and May 2013, who were treated with a new vancomycin CI regimen consisting of a loading dose of 35 mg/kg of body weight given as a 4-h infusion, followed by a daily CI dose adapted to creatinine clearance (CrCL), as estimated by the Cockcroft-Gault formula (median dose, 2,112 [1,500 to 2,838] mg). Vancomycin concentrations were measured at the end of the loading dose (T1), at 12 h (T2), at 24 h (T3), and the day after the start of therapy (T4). Vancomycin concentrations of 20 to 30 mg/liter at T2, T3, and T4 were considered adequate. A total of 107 patients (72% male) were included. Median age, weight, and CrCL were 59 (interquartile range [IQR], 48 to 71) years, 75 (IQR, 65 to 85) kg, and 94 (IQR, 56 to 140) ml/min, respectively. Vancomycin concentrations were 44 (IQR, 37 to 49), 25 (IQR, 21 to 32), 22 (IQR, 19 to 28), and 26 (IQR, 22 to 29) mg/liter at T1, T2, T3, and T4, respectively. Concentrations were adequate in 56% (60/107) of patients at T2, in 54% (57/105) at T3, and in 73% (41/56) at T4. This vancomycin regimen permitted rapid attainment of target concentrations in serum for most patients. Concentrations were insufficient in only 16% of patients at 12 h of treatment.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27216073      PMCID: PMC4958221          DOI: 10.1128/AAC.00330-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

1.  Augmented renal clearance in the Intensive Care Unit: an illustrative case series.

Authors:  Andrew A Udy; Michael T Putt; Sulochana Shanmugathasan; Jason A Roberts; Jeffrey Lipman
Journal:  Int J Antimicrob Agents       Date:  2010-03-21       Impact factor: 5.283

Review 2.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Am J Health Syst Pharm       Date:  2009-01-01       Impact factor: 2.637

3.  Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations*.

Authors:  Andrew A Udy; João P Baptista; Noelle L Lim; Gavin M Joynt; Paul Jarrett; Leesa Wockner; Robert J Boots; Jeffrey Lipman
Journal:  Crit Care Med       Date:  2014-03       Impact factor: 7.598

4.  Accuracy of weight and height estimation in an intensive care unit.

Authors:  L P Maskin; S Attie; M Setten; P O Rodriguez; I Bonelli; M E Stryjewski; R Valentini
Journal:  Anaesth Intensive Care       Date:  2010-09       Impact factor: 1.669

5.  Factors associated with inadequate early vancomycin levels in critically ill patients treated with continuous infusion.

Authors:  J J De Waele; I Danneels; P Depuydt; J Decruyenaere; M Bourgeois; E Hoste
Journal:  Int J Antimicrob Agents       Date:  2013-02-12       Impact factor: 5.283

6.  Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices.

Authors:  Meghan N Jeffres; Warren Isakow; Joshua A Doherty; Peggy S McKinnon; David J Ritchie; Scott T Micek; Marin H Kollef
Journal:  Chest       Date:  2006-10       Impact factor: 9.410

7.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens.

Authors:  Jason A Roberts; Fabio Silvio Taccone; Andrew A Udy; Jean-Louis Vincent; Frédérique Jacobs; Jeffrey Lipman
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

9.  Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections.

Authors:  Karine Berthoin; Els Ampe; Paul M Tulkens; Stephane Carryn
Journal:  Int J Antimicrob Agents       Date:  2009-09-26       Impact factor: 5.283

10.  Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?

Authors:  Andrew A Udy; Jeffrey Lipman; Paul Jarrett; Kerenaftali Klein; Steven C Wallis; Kashyap Patel; Carl M J Kirkpatrick; Peter S Kruger; David L Paterson; Michael S Roberts; Jason A Roberts
Journal:  Crit Care       Date:  2015-01-30       Impact factor: 9.097

View more
  15 in total

Review 1.  The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.

Authors:  T Tängdén; V Ramos Martín; T W Felton; E I Nielsen; S Marchand; R J Brüggemann; J B Bulitta; M Bassetti; U Theuretzbacher; B T Tsuji; D W Wareham; L E Friberg; J J De Waele; V H Tam; Jason A Roberts
Journal:  Intensive Care Med       Date:  2017-04-13       Impact factor: 17.440

2.  [Infections due to multidrug-resistant pathogens : Pathogens, resistance mechanisms and established treatment options].

Authors:  D C Richter; T Brenner; A Brinkmann; B Grabein; M Hochreiter; A Heininger; D Störzinger; J Briegel; M Pletz; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2019-10       Impact factor: 1.041

3.  Therapeutic drug monitoring of vancomycin in a patient on extracorporeal membrane oxygenation therapy in intensive care unit.

Authors:  L Herrera Hidalgo; A B Guisado Gil; M V Gil Navarro; L Martín Villén; Y Corcia Palomo; R Martín Bermúdez
Journal:  Eur J Clin Pharmacol       Date:  2018-05-07       Impact factor: 2.953

4.  [New antibiotics for severe infections due to multidrug-resistant pathogens : Definitive treatment and escalation].

Authors:  D C Richter; T Brenner; A Brinkmann; B Grabein; M Hochreiter; A Heininger; D Störzinger; J Briegel; M Pletz; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2019-11       Impact factor: 1.041

5.  Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations.

Authors:  Pieter J Colin; Karel Allegaert; Alison H Thomson; Daan J Touw; Michael Dolton; Matthijs de Hoog; Jason A Roberts; Eyob D Adane; Masato Yamamoto; Dolores Santos-Buelga; Ana Martín-Suarez; Nicolas Simon; Fabio S Taccone; Yoke-Lin Lo; Emilia Barcia; Michel M R F Struys; Douglas J Eleveld
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

Review 6.  Continuous Infusion Vancomycin in Pediatric Patients: A Critical Review of the Evidence.

Authors:  Heather L Girand
Journal:  J Pediatr Pharmacol Ther       Date:  2020

7.  Influence of Mechanical Ventilation on the Pharmacokinetics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients.

Authors:  Susanna Edith Medellín-Garibay; Silvia Romano-Moreno; Pilar Tejedor-Prado; Noelia Rubio-Álvaro; Aida Rueda-Naharro; Miguel Angel Blasco-Navalpotro; Benito García; Emilia Barcia
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

8.  Using a Vancomycin PBPK Model in Special Populations to Elucidate Case-Based Clinical PK Observations.

Authors:  Chie Emoto; Trevor N Johnson; Brooks T McPhail; Alexander A Vinks; Tsuyoshi Fukuda
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-02-15

9.  Target-Controlled Continuous Infusion for Antibiotic Dosing: Proof-of-Principle in an In-silico Vancomycin Trial in Intensive Care Unit Patients.

Authors:  Pieter J Colin; Stijn Jonckheere; Michel M R F Struys
Journal:  Clin Pharmacokinet       Date:  2018-11       Impact factor: 6.447

10.  Vancomycin pharmacokinetics in critically ill obese patients: can the clinician sit back and relax?

Authors:  Patrick M Honore; David De Bels; Luc Kugener; Sebastien Redant; Rachid Attou; Andrea Gallerani; Herbert D Spapen
Journal:  Crit Care       Date:  2019-01-17       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.